Erin J. Howell

Erin J. Howell

New York

Email [email protected]​

Phone +1 212 918 3634

Fax +1 212 918 3100

Practice groupCorporate & Finance

Erin Howell knows that a valuable adviser needs both breadth and depth of knowledge. Understanding her clients’ particular business is her key to advising clients across a broad range of industries on their most important corporate transactions, while maintaining a focus on the life sciences industry sector. 

Erin has counseled clients on a variety of transactional, business, and corporate matters, focusing on U.S. and international mergers and acquisitions, carve-out and asset purchase and sale transactions, and other transactional matters. Erin has represented clients in industries as varied as pharmaceuticals and life sciences, textiles, transportation, insurance, and health services, but brings a special depth to life sciences industry transactions. Her life sciences practice spans M&A, licensing transactions, and complex collaborations. The flexibility to transition between transaction structures allows her to provide seamless representation for her life sciences clients as their needs evolve.

*Currently on client secondment

Awards and recognitions


Legal Aid Society Recognition Award

Education and admissions


J.D., University of California, Berkeley School of Law, 2008

B.A., Michigan State University, summa cum laude, 2003


Member, LGBT Bar Association of Greater New York

Bar admissions and qualifications

New York

Representative experience

Helsinn Group on its strategic collaboration with BridgeBio Pharma Inc. affiliate QED Therapeutics, Inc. to co-develop and commercialize Infigratinib in oncology.

Novartis on its acquisition of Amblyotech, a U.S.-based software startup, pursuing the development of digital therapy for the treatment of amblyopia.

Medicines Development for Global Health on the sale of its Priority Review Voucher.

Novartis on its licensing and equity agreement with Boston Pharmaceuticals for the development of three novel anti-infective drug candidates.

Novartis in connection with a strategic collaboration with Cellular Biomedicine Group, Inc. to manufacture and supply the CAR-T cell therapy Kymriah® (tisagenlecleucel) in China.

Celgene on the entry into a strategic collaboration and licensing agreement with Kyn Therapeutics with an $80 million upfront payment.

Helsinn Healthcare SA in connection with the acquisition of the worldwide rights to Valchlor©/Ledaga© from Actelion Pharmaceuticals, Ltd.

Kiadis, a clinical stage biopharmaceutical company, on its acquisition of US-based CytoSen Therapeutics, Inc.

Elastagen Pty Ltd in relation to its sale to Allergan plc for up to US$260m.

Gemalto, on its acquisition of Smartrac's U.S. business.

A leading global life sciences company on its minority investment in a clinical lab, with an option to acquire.

Airbus, on its acquisition of MTM Robotics, a Seattle-based technology company that creates automated assembly and control systems.

A Bermuda-based reinsurance company in acquiring U.S. insurance companies.

A global transportation company in a strategic investment in a small business.

Regular representation of international property/casualty insurer in preparation of Holding Company Act filings.

A publicly held insurer in divesting non-core insurance business.

Loading data